Parathyroid hormone: Evolving therapeutic concepts

Current Opinion in Rheumatology

Volumn 16, Issue 4, 2004, Pages 457-463

  Lane, Nancy E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Osteoanabolic agent; Osteoporosis; Parathyroid hormone

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; NAFARELIN; PARATHYROID HORMONE; PREDNISOLONE; RECOMBINANT HORMONE; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG;

BONE MASS; BONE STRENGTH; BONE STRUCTURE; DIZZINESS; DRUG EFFICACY; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; LEG CRAMP; MEDICAL RESEARCH; NAUSEA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REDUCTION; REVIEW; RISK FACTOR; SURFACE PROPERTY;

CLINICAL TRIALS; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 3042629351     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000129721.98691.cb     Document Type: Review

References (25)

1. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
2. Lindsay R, Nieves J, Formica C, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
3. Buxton EC, Yao W, Lane NE: Changes in serum RANKL, OPG and IL-6 levels in glucocorticoid-induced osteoporosis patients treated with hPTH (1-34). Submitted to JCEM 12/2/03.
4. Li J, Duncan RL, Burr DB, et al.: Parathyroid hormone enhances mechanically induced bone formation through activation of L-type voltage-sensitive calcium channels. Am Soc Bone Miner Res 2002, September:20-24.
5. Watson PH, Kisiel M, Patterson EK, et al.: Expression of type I PTH/PTHrP receptors in the rat osteoclast and osteoclast like RAW 264.7 cells. Annual Meeting, ASBMR, 2002, San Antonio, Texas.
6. Buxton E, Fitzgerald I, Lane NE: Parathyroid hormone as a treatment for osteoporosis. Todays Ther Trends 2004, 21:345-372. Review of the preclinical and clinical studies that have been performed with parathyroid hormone-related fragments for the treatment of osteoporosis.
7. Lindsay R, Hodsman AB, Genant HK, et al.: A randomized controlled multicenter study of 1-84 hPTH for treatment of postmenopausal osteoporosis. Bone 1998, 23(suppl 1):S175.
8. Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
9. Fujita T, Inoue T, Morii H, et al.: Effect of intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999, 9:296-306.
10. Hodsman AB, Fraber LJ, Watson PH, et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997, 82:620-628.
11. Finkelstein JS, Klibanski A, Arnold AL, et al.: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998, 280:1067-1073.
12. Eli Lilly and Co: Forteo™ Prescribing Information. Available at: http://www. LillyMedical.com.
13. Jiang Y, Zhao J, Mitlak B, et al.: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941. This study demonstrates by both standard two-dimensional histomorphometry of iliac crest biopsies and three-dimensional micro-CT how parathyroid hormone treatment both thickens the trabecular and cortical bone diameter in addition to causing some cortical porosity.
14. Zanchetta JR, Bogado C, Ferretti JL, et al.: Effects of rhPTH (1-34) on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Bone 2002, 28:S86.
15. Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
16. Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
17. Black DM, Greenspan LS, Ensrud EK, et al.: N Engl J Med 2003, 49:1207-1215. The study finds parathyroid hormone and alendronate are not better than parathyroid hormone alone to increase bone mass in the lumbar spine by DXA or trabecular bone of the spine by QCT.
18. Cosman F, Nieves JW, Luckey MM, et al.: Daily versus cyclic PTH combined with alendronate versus alendronate along for treatment of osteoporosis. J Bone Miner Res 2003, S32.
19. Lane NE, Kelman A: A review of anabolic therapies for osteoporosis. Arthritis Res Ther 2003, 5:214-222. A thorough review of how new osteoanabolic agents work, including growth factors.
20. O'Neill TW, Felsenberg D, Varlow J, et al.: The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996, 11:1010-1018.
21. Slovik DM, Rosenthal DI, Doppelt SH, et al.: Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986, 1:377-381.
22. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
23. Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17. First study with large enough sample size to demonstrate the efficacy of parathyroid hormone in increasing lumbar spine BMD in men.
24. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226. First study to demonstrate in men with osteoporosis that combination therapy with parathyroid hormone and alendronate was not more effective than parathyroid hormone alone to increase lumbar spine bone mass.
25. Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.